Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 2017; 389: 1011–24.

Published: 26th April 2017

Authors: Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM et al.

Conclusion

In this study that included 730 patients, the addition of capecitabine improved median survival from 25.5 to 28 months (hazard ratio 0.82, 95 per cent confidence interval 0.68 to 0.98, P=0.032).

Pubmed Link

Your comments

0 Comments